Roche touts full data for drug in first-line PIK3CA-mutated breast cancer

Roche’s breast can­cer com­bi­na­tion of in­avolis­ib plus pal­bo­ci­clib and ful­ves­trant showed off new da­ta Fri­day, with the com­pa­ny tout­ing a 57% re­duc­tion in the risk of dis­ease pro­gres­sion or death in pa­tients with PIK3CA-mu­tat­ed HR-pos­i­tive HER2-neg­a­tive breast can­cer.

The Big Phar­ma is hop­ing in­avolis­ib is the first ap­proval for a first-line treat­ment in the dis­ease, which would pit it against No­var­tis’ Piqray, ap­proved in the sec­ond-line set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.